Hot Watch List: Apple Inc. (NASDAQ:AAPL), Twitter Inc (NYSE:TWTR), Gilead Sciences, Inc. (NASDAQ:GILD), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Apple Inc. (NASDAQ:AAPL)’s resurgent stock may have as much to do with financial engineering as the company’s technological wizardry. Monday marked Apple Inc. (NASDAQ:AAPL)’s first stock split in nine years, a move designed to make it more affordable to buy shares of the iPhone and iPad maker. Apple Inc. (NASDAQ:AAPL) stock performance was 1.60% in last session and finished the day at $93.70. Traded volume was 75.41million shares in the last session and the average volume of the stock remained 70.11million shares. The beta of the stock remained 0.93. Apple Inc. (NASDAQ:AAPL) insider ownership is 0.04%.

Twitter Inc (NYSE:TWTR), LinkedIn, Facebook, eBay, Google and Apple Inc. (NASDAQ:AAPL), all of which pay more than $5,000 a month, or $60,000 annually if these were full time jobs. Twitter Inc (NYSE:TWTR) rose 3.42 percent to $34.47 Monday on volume of 23.40million shares. The intra-day range of the stock was $33.09 to $34.55. Twitter Inc (NYSE:TWTR) has a market capitalization of $20.31billion.

Gilead Sciences, Inc. (NASDAQ:GILD) which makes almost half its revenue from hepatitis C drug Sovaldi, closed about 4% lower. One in 100 Americans have chronic hep C infections, according to the Centers for Disease Control. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on June 09, 2014 reported a decrease of -4.11% to the closing price of $79.00. Its fifty two weeks range is $46.70 -$84.88. The total market capitalization recorded $121.33billion. The overall volume in the last trading session was 23.33million shares. In its share capital, GILD has 1.54billion outstanding shares.

The stock price of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) another small company developing hepatitis C drugs, climbed more than 47 percent on speculation that it would be bought by a company that lost out in the bidding for Idenix. On Monday, shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) advanced 47.57% to close the day at $4.25. Company monthly performance is recorded as 68.65%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) quarterly revenue growth is 28.40%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone